Patrick O'Leary, PhD

Title(s)Specialist, HDF Comprehensive Cancer Ctr
SchoolSchool of Medicine
Address1450 Third St, #207
San Francisco CA 94158
Phone415-502-3579
ORCID ORCID Icon0000-0002-2919-5943 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University College Dublin, Dublin, IrelandPhD09/2013Cancer Biology
    University College Dublin , Dublin, IrelandBSc06/2009Pharmacology

    Collapse Overview 
    Collapse Overview
    Cancer biologist with a focus on using CRISPR screening to develop targeted therapeutics for cancers with mutations in DNA repair genes, and to study mechanisms of resistance to these therapies. Passionate about science education & outreach, strengthening community and exploring the outdoors.

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2. Cancer Res. 2022 11 02; 82(21):3950-3961. O'Leary PC, Chen H, Doruk YU, Williamson T, Polacco B, McNeal AS, Shenoy T, Kale N, Carnevale J, Stevenson E, Quigley DA, Chou J, Feng FY, Swaney DL, Krogan NJ, Kim M, Diolaiti ME, Ashworth A. PMID: 36273492; PMCID: PMC9633439.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    2. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature. 2022 09; 609(7925):174-182. Carnevale J, Shifrut E, Kale N, Nyberg WA, Blaeschke F, Chen YY, Li Z, Bapat SP, Diolaiti ME, O'Leary P, Vedova S, Belk J, Daniel B, Roth TL, Bachl S, Anido AA, Prinzing B, Ibañez-Vega J, Lange S, Haydar D, Luetke-Eversloh M, Born-Bony M, Hegde B, Kogan S, Feuchtinger T, Okada H, Satpathy AT, Shannon K, Gottschalk S, Eyquem J, Krenciute G, Ashworth A, Marson A. PMID: 36002574; PMCID: PMC9433322.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimalsCells
    3. A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor. Mol Cancer Ther. 2022 07 05; 21(7):1076-1089. Chen H, Diolaiti ME, O'Leary PC, Rojc A, Krogan NJ, Kim M, Ashworth A. PMID: 35439318; PMCID: PMC9769698.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    4. A protein interaction landscape of breast cancer. Science. 2021 Oct; 374(6563):eabf3066. Kim M, Park J, Bouhaddou M, Kim K, Rojc A, Modak M, Soucheray M, McGregor MJ, O'Leary P, Wolf D, Stevenson E, Foo TK, Mitchell D, Herrington KA, Muñoz DP, Tutuncuoglu B, Chen KH, Zheng F, Kreisberg JF, Diolaiti ME, Gordan JD, Coppé JP, Swaney DL, Xia B, van 't Veer L, Ashworth A, Ideker T, Krogan NJ. PMID: 34591612; PMCID: PMC9040556.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    5. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. BMC Cancer. 2018 Oct 11; 18(1):965. Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O'Leary P, Holmes FA, Espina V, Liotta LA, O'Shaughnessy J, Gallagher C, O'Driscoll L, Rani S, Madden SF, O'Brien NA, Ginther C, Slamon D, Walsh N, Gallagher WM, Zagozdzon R, Watson WR, O'Donovan N, Crown J. PMID: 30305055; PMCID: PMC6180577.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    6. Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents. Br J Cancer. 2018 10; 119(7):873-884. Bajor M, Zych AO, Graczyk-Jarzynka A, Muchowicz A, Firczuk M, Trzeciak L, Gaj P, Domagala A, Siernicka M, Zagozdzon A, Siedlecki P, Kniotek M, O'Leary PC, Golab J, Zagozdzon R. PMID: 30287919; PMCID: PMC6189216.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    7. High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients. Melanoma Res. 2015 Jun; 25(3):189-99. van den Hurk K, Balint B, Toomey S, O'Leary PC, Unwin L, Sheahan K, McDermott EW, Murphy I, van den Oord JJ, Rafferty M, FitzGerald DM, Moran J, Cummins R, MacEneaney O, Kay EW, O'Brien CP, Finn SP, Heffron CC, Murphy M, Yela R, Power DG, Regan PJ, McDermott CM, O'Keeffe A, Orosz Z, Donnellan PP, Crown JP, Hennessy BT, Gallagher WM. PMID: 25746038.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    8. Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer. Breast Cancer Res. 2014 Jul 10; 16(4):R79. O'Leary PC, Terrile M, Bajor M, Gaj P, Hennessy BT, Mills GB, Zagozdzon A, O'Connor DP, Brennan DJ, Connor K, Li J, Gonzalez-Angulo AM, Sun HD, Pu JX, Pontén F, Uhlén M, Jirström K, Nowis DA, Crown JP, Zagozdzon R, Gallagher WM. PMID: 25011585; PMCID: PMC4226972.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    9. Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer. BMC Cancer. 2013 Apr 02; 13:175. O Leary PC, Penny SA, Dolan RT, Kelly CM, Madden SF, Rexhepaj E, Brennan DJ, McCann AH, Pontén F, Uhlén M, Zagozdzon R, Duffy MJ, Kell MR, Jirström K, Gallagher WM. PMID: 23547718; PMCID: PMC3668187.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    10. Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic mice. BMC Cancer. 2012 May 30; 12:209. Zagozdzon AM, O'Leary P, Callanan JJ, Crown J, Gallagher WM, Zagozdzon R. PMID: 22646761; PMCID: PMC3411433.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    11. Topoisomerase I amplification in melanoma is associated with more advanced tumours and poor prognosis. Pigment Cell Melanoma Res. 2010 Aug; 23(4):542-53. Ryan D, Rafferty M, Hegarty S, O'Leary P, Faller W, Gremel G, Bergqvist M, Agnarsdottir M, Strömberg S, Kampf C, Pontén F, Millikan RC, Dervan PA, Gallagher WM. PMID: 20465595.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    Work in Global Health Equity

    Offer Student Projects

    See more options in the Advanced Search tab

    Patrick's Networks
    Concepts (100)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (21)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.